Whitehawk Therapeutics Inc. announced new data from a real-world analysis evaluating Protein Tyrosine Kinase 7 (PTK7) as a broadly expressed and clinically relevant target across solid tumors. The findings, presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, indicate that PTK7 is the third most highly expressed tumor marker among clinically validated and emerging antibody drug conjugate $(ADC)$ targets, present in approximately 70% of tumors. PTK7 expression was found to be stable across different histologic subtypes, disease stages, and metastatic statuses in cancers such as lung, ovarian, and endometrial. Whitehawk Therapeutics is developing HWK-007, a PTK7-targeting ADC utilizing a cleavable linker for delivery of a Topoisomerase I inhibitor payload, with plans to submit an Investigational New Drug application to the U.S. Food and Drug Administration by year-end and initiate clinical evaluation in non-small cell lung cancer, ovarian, and endometrial cancers.